BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

925 related articles for article (PubMed ID: 23948462)

  • 1. The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
    Teo M; Karakaya E; Young CA; Dyker KE; Coyle C; Sen M; Prestwich RJ
    Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):647-53. PubMed ID: 23948462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery and concurrent chemoradiotherapy improves outcome of recurrent advanced head and neck squamous cell carcinoma.
    Yang WC; Chen CH; Tang JY; Wu CF; Liu YC; Sun Y; Lin SF
    Anticancer Res; 2014 Jul; 34(7):3765-73. PubMed ID: 24982400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status.
    Lowe NM; Bernstein JM; Mais K; Garcez K; Lee LW; Sykes A; Thomson DJ; Homer JJ; West CM; Slevin NJ
    J Cancer Res Clin Oncol; 2018 Feb; 144(2):389-401. PubMed ID: 29222650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer.
    Wang HM; Lin CY; Hsieh CH; Hsu CL; Fan KH; Chang JT; Huang SF; Kang CJ; Liao CT; Ng SH; Yen TC
    J Formos Med Assoc; 2017 Mar; 116(3):185-192. PubMed ID: 27133181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
    Prestwich RJ; Öksüz DÇ; Dyker K; Coyle C; Şen M
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e237-43. PubMed ID: 21620580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
    Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
    Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck.
    Komatsu M; Shiono O; Taguchi T; Sakuma Y; Nishimura G; Sano D; Sakuma N; Yabuki K; Arai Y; Takahashi M; Isitoya J; Oridate N
    Jpn J Clin Oncol; 2014 May; 44(5):416-21. PubMed ID: 24688084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
    Katori H; Tsukuda M
    Clin Oncol (R Coll Radiol); 2005 May; 17(3):148-52. PubMed ID: 15900997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
    Kim R; Hahn S; Shin J; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS
    Cancer Res Treat; 2016 Jul; 48(3):907-16. PubMed ID: 26582394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
    Lorch JH; Goloubeva O; Haddad RI; Cullen K; Sarlis N; Tishler R; Tan M; Fasciano J; Sammartino DE; Posner MR;
    Lancet Oncol; 2011 Feb; 12(2):153-9. PubMed ID: 21233014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
    Hitt R; Grau JJ; López-Pousa A; Berrocal A; García-Girón C; Irigoyen A; Sastre J; Martínez-Trufero J; Brandariz Castelo JA; Verger E; Cruz-Hernández JJ;
    Ann Oncol; 2014 Jan; 25(1):216-25. PubMed ID: 24256848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases.
    Izawa N; Onozawa Y; Hikosaka T; Hamauchi S; Tsushima T; Todaka A; Machida N; Haraguchi Y; Ogawa H; Nishimura T; Nakagawa M; Fuke T; Iida Y; Kamijo T; Onitsuka T; Boku N; Yasui H; Yokota T
    Int J Clin Oncol; 2015 Jun; 20(3):455-62. PubMed ID: 25248339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
    Takácsi-Nagy Z; Hitre E; Remenár É; Oberna F; Polgár C; Major T; Gödény M; Fodor J; Kásler M
    Strahlenther Onkol; 2015 Aug; 191(8):635-41. PubMed ID: 25782685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective phase II randomized study of docetaxel combined with lobaplatin versus TPF regimen induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
    Zhang M; Chen Y; Wu W; Jin F; Li Y; Long J; Luo X; Gong X; Chen X; Liu L; Tang H; Wang Z
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):18081-18091. PubMed ID: 37985501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma.
    Nakahara S; Takenaka Y; Ogawa K; Nishiike S; Yamamoto Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Yoshii T; Tomiyama Y; Inohara H
    Int J Clin Oncol; 2016 Dec; 21(6):1030-1037. PubMed ID: 27306220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
    Posner MR; Hershock DM; Blajman CR; Mickiewicz E; Winquist E; Gorbounova V; Tjulandin S; Shin DM; Cullen K; Ervin TJ; Murphy BA; Raez LE; Cohen RB; Spaulding M; Tishler RB; Roth B; Viroglio Rdel C; Venkatesan V; Romanov I; Agarwala S; Harter KW; Dugan M; Cmelak A; Markoe AM; Read PW; Steinbrenner L; Colevas AD; Norris CM; Haddad RI;
    N Engl J Med; 2007 Oct; 357(17):1705-15. PubMed ID: 17960013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
    Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.
    Karakaya E; Yetmen O; Oksuz DC; Dyker KE; Coyle C; Sen M; Prestwich RJ
    Oral Oncol; 2013 Jan; 49(1):55-9. PubMed ID: 22858313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer.
    Herman LC; Chen L; Garnett A; Feldman LE; Smith B; Weichselbaum RR; Spiotto MT
    Oral Oncol; 2014 Jan; 50(1):52-8. PubMed ID: 24055193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.
    Nishimura G; Taguchi T; Takahashi M; Shiono O; Komatsu M; Sano D; Yabuki K; Arai Y; Takahashi H; Hata M; Oridate N
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1315-9. PubMed ID: 27154176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.